Pivekimab (CAS 2234335-84-1) is a human IgG1 monoclonal antibody that targets IL-3 and CD123 on tumor cells, inhibits tumor growth, and helps the immune system destroy cancer cells. It is used to make Pivekimab sunirine, a CD123-targeted antibody-drug conjugate (ADC). This conjugate delivers a cytotoxic drug directly to IL-3 receptor-expressing tumors, improving treatment effectiveness and reducing side effects.
Key Features:
- Target Specificity: Binds to IL-3 and CD123 on tumor cells.
- Mechanism of Action: Inhibits tumor growth and enhances immune destruction.
- Conjugate: Combined with a cytotoxic agent in Pivekimab sunirine for targeted delivery.
Applications:
- Cancer Therapy: Used in studying blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other IL-3 receptor-expressing cancers.
- Antibody-Drug Conjugates (ADCs): Targets tumor cells for chemotherapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
